<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01120847</url>
  </required_header>
  <id_info>
    <org_study_id>SU-06302009-2920</org_study_id>
    <nct_id>NCT01120847</nct_id>
  </id_info>
  <brief_title>Post Traumatic Stress Disorder (PTSD), Sleep Disordered Breathing And Genetics: Effects On Cognition</brief_title>
  <official_title>PTSD, Sleep Disordered Breathing And Genetics: Effects On Cognition</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>US Department of Veterans Affairs</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The current research program aims to study how sleep disordered breathing, age and genetics&#xD;
      affect memory in older adult veterans with Posttraumatic Stress Disorder (PTSD).&#xD;
&#xD;
      The study will help researchers and clinicians better understand the relationship among PTSD,&#xD;
      sleep disordered breathing, genetics and memory function.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The research project will clarify how sleep disordered breathing and Apolipoprotein (APOE)&#xD;
      status affect cognitive decline in a population already at risk for accelerated&#xD;
      decline-veterans with PTSD.&#xD;
&#xD;
      To fill this knowledge gap properly, we will conduct a longitudinal study and data include&#xD;
      analytic techniques designed specifically to identify moderators and mediators of clinical&#xD;
      change.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 2004</start_date>
  <completion_date type="Actual">March 10, 2017</completion_date>
  <primary_completion_date type="Actual">March 10, 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Rey Auditory Verbal Learning Test-Measures auditory learning and memory</measure>
    <time_frame>annually</time_frame>
    <description>This scale measures auditory learning and memory. The raw score range is 0-15 and scaled score range is 0-19.For raw and scaled scores, higher values represent a better outcome. Subscales are not combined to compute a composite score.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>APOE status</measure>
    <time_frame>sample taken at entry into study.</time_frame>
    <description>APOE allele</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">324</enrollment>
  <condition>Stress Disorders, Post-Traumatic</condition>
  <arm_group>
    <arm_group_label>Veterans with PTSD</arm_group_label>
    <description>No intervention; this is an observational study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group w/out PTSD</arm_group_label>
    <description>No intervention; this is an observational study.</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      blood or saliva&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        US war Veterans with PTSD and possible sleep problems&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age 55 years or older, male or female veterans of any racial or ethnic group.&#xD;
&#xD;
          2. PTSD subjects will be positive for lifetime PTSD, related to any past lifetime&#xD;
             traumatic experience and have a diagnosis of current, chronic PTSD by the Clinician&#xD;
             Administered PTSD Scale (CAPS) criteria with current CAPS score &gt; 40&#xD;
&#xD;
          3. Capable of giving informed consent for the study&#xD;
&#xD;
          4. Sufficient visual and auditory acuity for cognitive testing&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Psychiatric Exclusions:&#xD;
&#xD;
          1. Current or lifetime history of any psychiatric disorder with psychotic features&#xD;
&#xD;
          2. Current or lifetime bipolar disorder or delusional disorder&#xD;
&#xD;
          3. Prominent suicidal or homicidal ideation&#xD;
&#xD;
          4. Current exposure to trauma or recent exposure to trauma in the past 3 months.&#xD;
&#xD;
          5. Currently or have within the past six months met DSM-IV criteria for drug or alcohol&#xD;
             abuse or dependence (except nicotine).&#xD;
&#xD;
          6. Presence of alcohol intoxication (by breathalyzer) or alcohol withdrawal (by exam)&#xD;
             during testing&#xD;
&#xD;
          7. Diagnosis of probable or possible dementia&#xD;
&#xD;
          8. Mini-Mental State Exam (MMSE) &lt; 23&#xD;
&#xD;
          9. History of seizure disorder.&#xD;
&#xD;
        Medical/Medication Exclusions:&#xD;
&#xD;
          1. Acute illness or unstable chronic illness (e.g., history of severe liver disease&#xD;
             (cirrhosis, esophageal varices, ascites, portal hypertension, hepatic encephalopathy).&#xD;
             Clinical or laboratory evidence of active hepatic disease will be recorded.&#xD;
&#xD;
          2. History of neurologic (e.g., multiple sclerosis, seizure disorder, stroke, history of&#xD;
             transient ischemic attacks) or systemic illness affecting central nervous system (CNS)&#xD;
             function (e.g. liver failure, kidney failure, congestive heart failure, systemic&#xD;
             cancer)&#xD;
&#xD;
          3. Unstable or severe cardiovascular disease&#xD;
&#xD;
          4. Unstable gastrointestinal disorder&#xD;
&#xD;
          5. Uncontrolled hypertension&#xD;
&#xD;
          6. Head injury within one year&#xD;
&#xD;
          7. Loss of consciousness &gt;24 hrs&#xD;
&#xD;
          8. Use of systemic steroid medication (with the exception of Estrogen replacement therapy&#xD;
             which is permissible)&#xD;
&#xD;
          9. Illiterate or unable to read or write English or are judged by the investigator to be&#xD;
             unable or unlikely to follow the study protocol&#xD;
&#xD;
         10. Toxicology evidence of illicit substance use.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jerome A Yesavage</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>VA Palo Alto Health Care System</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>May 7, 2010</study_first_submitted>
  <study_first_submitted_qc>May 10, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 11, 2010</study_first_posted>
  <last_update_submitted>February 26, 2020</last_update_submitted>
  <last_update_submitted_qc>February 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Jerome A Yesavage,</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sleep Apnea Syndromes</mesh_term>
    <mesh_term>Stress Disorders, Traumatic</mesh_term>
    <mesh_term>Stress Disorders, Post-Traumatic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

